$ACTG Balance Sheet | Understand Stock

$ACTG

$4.16 -$0.05 (1.19%) Close

$ACTG Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash
Equity securities
Investment securities - equity method investments
Equity securities without readily determinable fair value
Equity method investments
Investment at fair value
Loans receivable
Accounts receivable, net
Other receivable (Note 3)
Inventories
Prepaid expenses and other current assets
Total current assets

Long-term restricted cash
Patents, net of accumulated amortization
Property, plant and equipment, net
Oil and natural gas properties, net
Goodwill
Net Book Value
Operating lease, right-of-use assets
Deferred income tax assets, net
Other non-current assets
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Accrued compensation
Accrued patent investment costs
Current asset retirement obligation
Royalties and contingent legal fees payable
Accrued patent costs
Deferred revenue
Senior secured notes payable
Accrued loss contingency
Current portion of long-term debt
Total current liabilities

Deferred revenue, net of current portion
Series A warrant liabilities
Series A embedded derivative liabilities
Series B warrant liabilities
Asset retirement obligation
Long-term lease liabilities
Deferred income tax liabilities, net
Benchmark revolving credit facility
Deflecto facility
Other long-term liabilities
Total liabilities
Series A redeemable convertible preferred stock, par value $0.001 per share; stated value $100 per share; zero and 350,000 shares authorized, issued and outstanding as of December 31, 2023 and 2022, respectively; aggregate liquidation preference of zero and $35,000 as of December 31, 2023 and 2022, respectively
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding
Common stock, par value $0.001 per share; 300,000,000 shares authorized; 97,586,805 and 96,475,469 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Treasury stock, at cost, 20,542,064 shares as of June 30, 2026 and December 31, 2025
Accumulated other comprehensive income
Additional paid-in capital
Accumulated deficit
Total Acacia Research Corporation stockholders' equity
Noncontrolling interests
Total stockholders' equity

Total liabilities and stockholders' equity
Treasury Stock, Common, Shares

Comments